Open-label phase II study of everolimus plus endocrine therapy in post-menopausal women with ER+, HER2-metastatic breast cancer (Chloe trial)

被引：0
|
作者：
Shien, T. [1 ]
Shimomura, A. [2 ]
Uemura, Y. [3 ]
Kato, H. [4 ]
Kitada, M. [5 ]
Kikawa, Y. [6 ]
Shiba, E. [7 ]
Yoshida, T. [8 ]
Morimoto, T. [9 ]
Toyama, T. [10 ]
Aihara, T. [11 ]
Mukai, H. [12 ]
机构：
[1] Okayama Univ Hosp, Breast & Endocrine Surg, Okayama, Japan
[2] Natl Canc Ctr, Breast & Med Oncol, Tokyo, Japan
[3] Tokyo Univ Hosp, Biostat, Clin Res Support Ctr, Tokyo, Japan
[4] Teine Keijinkai Hosp, Thorac Surg, Sapporo, Hokkaido, Japan
[5] Asahikawa Med Univ, Surg, Asahikawa, Hokkaido, Japan
[6] Gen Hosp, Kobe City Med Ctr, Breast Surg, Kobe, Hyogo, Japan
[7] Osaka Breast Clin, Surg, Osaka, Japan
[8] Kanagawa Canc Ctr, Breast & Endocrine Surg, Yokohama, Kanagawa, Japan
[9] Yao Municipal Hosp, Breast Surg, Osaka, Japan
[10] Nagoya City Univ, Grad Sch Med Sci, Breast Surg, Nagoya, Aichi, Japan
[11] Keimeikai Aihara Hosp, Surg, Osaka, Japan
[12] Natl Canc Ctr Hosp East, Breast & Med Oncol, Kashiwa, Chiba, Japan
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
313TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer
    Chan, Arlene
    Shannon, Catherine
    de Boer, Richard
    Baron-Hay, Sally
    Redfern, Andrew
    Bauwens, Astrid
    Craft, Paul
    Webb, Suzanne
    Townsend, Amanda
    Kotasek, Dusan
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 (04) : 368 - 375
  • [32] Everolimus plus endocrine vs endocrine therapy in treatment advanced ER+, HER2-breast cancer patients: A meta-analysis
    Wang, Na
    Wang, Kai
    Liu, Ya-ting
    Song, Fei-xue
    CURRENT PROBLEMS IN CANCER, 2019, 43 (02) : 106 - 114
  • [33] An open-label, phase II study of rucaparib, a PARP inhibitor, in HER2-metastatic breast cancer patients with high genomic loss of heterozygosity: RUBY
    Patsouris, Anne
    Vicier, Cecile
    Campion, Loic
    Gouraud, Wilfried
    Jimenez, Marta
    Pezzella, Veronica
    Loehr, Andrea
    Raponi, Mitch
    Bieche, Ivan
    Callens, Celine
    Andre, Fabrice
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [34] An open-label, phase II study of rucaparib, a PARP inhibitor, in HER2-metastatic breast cancer patients with high genomic loss of heterozygosity.
    Patsouris, Anne
    Tredan, Olivier
    Campion, Loic
    Goncalves, Anthony
    Arnedos, Monica
    Sablin, Marie Paule
    Jezequel, Pascal
    Jimenez, Marta
    Pezzella, Veronica
    Bieche, Ivan
    Callens, Celine
    Loehr, Andrea
    Nenciu, Daniel
    Vicier, Cecile
    Andre, Fabrice
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [35] Eribulin mesylate plus capecitabine for adjuvant treatment in post-menopausal ER plus early-stage breast cancer: A phase 2, multicenter, open-label study using 2 different dosage regimens
    Smith, John W., II
    Vukelja, Svetislava
    Hoffman, Anthony
    Jones, Vicky
    McIntyre, Kristi
    Berrak, Erhan
    Teng, Angela
    Cox, David
    O'Shaughnessy, Joyce
    CANCER RESEARCH, 2015, 75
  • [36] Femara plus ribociclib or placebo as neoadjuvant endocrine therapy for women with ER+, HER2-negative early breast cancer - The Feline trial
    Khan, Q. J.
    Prochaska, L. H.
    Mohammad, J.
    Yuan, Y.
    O'Dea, A.
    Bardia, A.
    Wisinski, K.
    Hard, M.
    Baccaray, S.
    Makhoul, I.
    Wagner, J.
    Laura, S.
    Ma, C.
    Sharma, P.
    CANCER RESEARCH, 2017, 77
  • [37] The Future of ER+/HER2-Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors
    Stravodimou, Athina
    Voutsadakis, Ioannis A.
    ANTICANCER RESEARCH, 2020, 40 (09) : 4829 - 4841
  • [38] Endocrine therapy in post-menopausal women with metastatic breast cancer: From literature and guidelines to clinical practice
    Sini, Valentina
    Cinieri, Saverio
    Conte, Pierfranco
    De Laurentiis, Michelino
    Di Leo, Angelo
    Tondini, Carlo
    Marchetti, Paolo
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 100 : 57 - 68
  • [39] Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) plus palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2-eBC): Interim analysis of the randomised, open-label, phase II coopERA BC study
    Hurvitz, S. A.
    Park, Y. H.
    Bardia, A.
    Quiroga, V.
    Lopez-Valverde, V.
    Steinseifer, J.
    Moore, H. M.
    Spera, G.
    Xue, C.
    Fasching, P. A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1285 - S1286
  • [40] Quantitative evaluation of the efficacy and safety profiles of two types of targeted inhibitors combined with endocrine therapy in ER+/HER2-metastatic breast cancer
    Pan, Meiyu
    Lin, Yan
    Liu, Yinhui
    Xu, Ruijuan
    Yang, Jin
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 80 (09) : 1387 - 1397
12345